InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,167.20
(
1.82%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.63
(
0.11%
)
Bitcoin
59,288.42
(
1.80%
)

Replies to post #182308 on Biotech Values

Replies to #182308 on Biotech Values

DewDiligence

10/01/14 9:56 AM

#182319 RE: Double_Bagel #182308

MNTA…cash is going to run out soon without Copaxone approval.

Not true—MNTA is not running out of cash anytime soon. At 6/30/14, MNTA had $223M of cash (including $20.7M of restricted cash). During 2H14, operating cash burn (assuming zero Copaxone sales) is projected to be $52M, and $19M of milestones are expected from BAX for the FoB program, resulting in an expected year-end cash balance of $190M (including the restricted cash).